DiscGenics tests injectable disc cell therapy for degenerative disc disease

Written by Alan Condon | July 10, 2019 | Print  |

Biotechnology company DiscGenics treated the first Utahns in its nationwide clinical study of injectable disc cell therapy for degenerative disc disease.

The study aims to determine the safety and efficacy of IDCT — a homologous and allogenic cell therapy — in the treatment of mild to moderate degenerative disc disease.

Patients were treated at The Smart Clinic in Draper, Utah, which is managed by Physicians' Research Options.

"Developing IDCT has been a true labor of love for the team here in Salt Lake," said Flagg Flanagan, CEO and chairman of the board of directors for DiscGenics. "We have the potential to not only make a significant impact on the health and wellness of our neighbors suffering from chronic low back pain, but to also play a small role in combating the opioid crisis in our own backyard."

More articles on biologics:
California Institute for Regenerative Medicine expected to run out of money — 4 insights
Federal court bans Florida stem cell company from treating patients, including spinal cord injury
NervGen Pharma launches MS program focusing on nerve remyelination — 3 things to know

© Copyright ASC COMMUNICATIONS 2019. Interested in LINKING to or REPRINTING this content? View our policies here.

Top 40 Articles from the Past 6 Months